$XLO News

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

Xilio Therapeutics Q1 EPS $(0.58) Beats $(0.66) Estimate, Sales $12.648M Beat $8.520M Estimate

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Xilio's XTX601 Shows Tumor-Selective Activation And Strong Preclinical Anti-Tumor Activity With Favorable Safety Profile At AACR 2026

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Xilio Therapeutics Q4 EPS $0.81 Beats $(0.12) Estimate, Sales $13.686M Beat $7.960M Estimate

Xilio Therapeutics Announces XTX501 Shows Robust Monotherapy Activity; Plans IND Submission In Middle Of 2026; Intends To Start Phase 1 Study Of XTX501 In H2 This Year

Xilio Therapeutics shares are trading higher after the company announced an upcoming poster presentation entitled "Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager" at the American Association for Cancer Research annual meeting from April 17-22, 2026.

Xilio Therapeutics shares are trading higher after the company announced an upcoming poster presentation entitled "Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager" at the American Association for Cancer Research annual meeting from April 17-22, 2026.

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Xilio Therapeutics Announces 1-For-14 Reverse Stock Split, Effective March 13

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Reported Earlier, Xilio Therapeutics Prices Underwritten Offering Of 74,780,300 Pre-Funded Warrants At $0.5349 Per Warrant For $40M Gross Proceeds

Xilio Therapeutics Announces Pricing of Underwritten Offering